Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).

Nick Pavlakis,Federica Grosso,Nicola Steele,Anna K. Nowak,Silvia Novello,Sanjay Popat,L. Greillier,Martin Reck,Thomas John,Paul Taylor,Natasha B. Leighl,Giovanni Luca Ceresoli,Jens Benn Sørensen,David Planchard,Brett Hughes,Julien Mazieres,Mark A. Socinski,Ute von Wangenheim,José Barrueco,Giorgio V. Scagliotti

Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) vs. placebo (P) in combination with first-line pemetrexed/cisplatin (PEM/CIS) in patients (pts) with malignant pleural mesothelioma (MPM).

2018

8568Background: We evaluated the relationship between PFSR and OS in the Phase II part of LUME-Meso, a double-blind, placebo-controlled study that showed improved PFS (primary endpoint; hazard rati...

Keywords:

Pemetrexed
Progression-free survival
Physical therapy
Mesothelioma
Placebo
Cisplatin
Medicine
Cancer research
Lume
Nintedanib
Clinical endpoint
Oncology
first line
Internal medicine
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations